Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?

Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?

Based on ODYSSEY Outcomes,which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Ulf Landmesser MD, FESC

Ulf Landmesser MD, FESC

Professor of Cardiology Medical Director, Department of Cardiology Charite University Hospital Berlin, Germany